Skip to content

Effect of Alfentanil on cardiac Troponin in patients treated with Electroconvulsive therapy

Effect of alfentanil on cardiac troponin in patients treated with Electroconvulsive therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201112248504N1
Enrollment
120
Registered
2017-01-27
Start date
2015-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mood [affective] disorders. Mood [affective] disorders

Interventions

Intervention 1: We inject 10microgeram in kilogram intravenous Alfentanil of 10 milliliter and ?Electroconvulsive therapy in intervention group. Intervention 2: We inject 1 milliliter of placebo (Norm
Treatment - Drugs
Placebo
We inject 10microgeram in kilogram intravenous Alfentanil of 10 milliliter and ?Electroconvulsive therapy in intervention group.
We inject 1 milliliter of placebo (Normal saline) and Electroconvulsive therapy ?treatment protocol in control group.

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Hospitalized patients, who have mood disorder confirmed by ?psychiatrist according to DSM-IV-TR criteria and have Electroconvulsive ?therapy indication; ASA I and II; 20 to 60 years??.? Exclusion criteria: Patient's unwillingness to participate in study; pregnancy; ?heart failure; other conditions resulting in myocardial cell damage leading to an ?increase in Troponin I include myocarditis, cardiac surgery, angina, unstable ?angina, congestive heart failure and non-cardiac causes such as kidney failure; ?chronic diseases; musculoskeletal and pulmonary embolism; uncontrolled ?hypertension and hypertension; active gastrointestinal ulcer or bleeding, ?Inflammatory bowel disease; history of severe kidney or liver failure; ?concomitant use of corticosteroids; intracranial hemorrhage or stroke; unstable ?vascular aneurysms; neurological diseases (bulky mass or a history of seizure ?disorders); severe lung problems; ASA class IV and V; smokers with Chronic ?Obstructive Pulmonary Disease; receiving Electroconvulsive therapy in the ?last 2 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Heart Rate. Timepoint: Before drug administration, before and after Electroconvulsive therapy ?. Method of measurement: beat per minute.;Mean arterial pressure. Timepoint: Before drug administration, before and after Electroconvulsive therapy ?. Method of measurement: millimeter Hg.;Diastolic blood pressure. Timepoint: Before drug administration, before and after ECT. Method of measurement: mmHg.;Cardiac Troponin. Timepoint: Before drug administration, before and after Electroconvulsive therapy ?. Method of measurement: Micrograms per liter.;Systolic blood pressure. Timepoint: Before drug administration, before and after Electroconvulsive therapy ?. Method of measurement: millimeter Hg.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Damanpak Moghaddam

Arak University of Medical Sciences

vdamanpak@yahoo.com+98 89 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026